H. Gschaidmeier

发表

Everolimus in patients with autosomal dominant polycystic kidney disease.

Martin Büchert, Kai-Uwe Eckardt, Klemens Budde, 2010, The New England journal of medicine.

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

P. Paschka, D. Hossfeld, H. Gschaidmeier, 2003, Leukemia.

The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.

S. Drechsler, H. Gschaidmeier, S. Ladenburger, 2007, European journal of pharmacology.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

B. Druker, C. Schoch, A. Corbin, 2002, Leukemia.

Density-dependent growth of normal and nodular hepatocytes.

H. Gschaidmeier, K. Bock, B. Bock-Hennig, 2000, Toxicology.

Imatinib restores expression of CD62L in BCR‐ABL‐positive cells

P. Paschka, A. Ho, H. Gschaidmeier, 2003, Journal of leukocyte biology.

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Martin C. Müller, S. Wölfl, H. Gschaidmeier, 2003 .

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

P. Paschka, C. Schoch, H. Gschaidmeier, 2002, Leukemia.

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

W. Siegert, G. Ledderose, H. Gschaidmeier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.

Martin C. Müller, S. Wölfl, H. Gschaidmeier, 2003, Blood.

Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome

D. Huhn, M. Schwarz, K. Kreuzer, 2003, American journal of hematology.

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C

H. Gschaidmeier, S. Kasper, F. Breitenbuecher, 2003, Leukemia.

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

H. Gschaidmeier, C. Thiede, A. Hochhaus, 2003, Bone Marrow Transplantation.

Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.

H. Gschaidmeier, C. Huber, T. Fischer, 2003, The Keio journal of medicine.

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)

H. Gschaidmeier, C. Huber, T. Fischer, 2002, Leukemia.

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

H. Gschaidmeier, B. Wassmann, D. Hoelzer, 2001, Bone Marrow Transplantation.

Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.

A. Marx, H. Gschaidmeier, C. Peschel, 2004, Blood.

ALL ) with the Abl-tyrosine kinase inhibitor STI 571 ( Glivec ) + leukemia ( Ph Philadelphia chromosome / Bcr-Bbl positive acute lymphoblastic Early minimal residual disease ( MRD ) analysis during treatment

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2002 .

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

T. Leblanc, H. Gschaidmeier, J. Starý, 2006, Leukemia.

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.

P. Paschka, K. Dietz, C. Bokemeyer, 2003, Blood.

Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia

P. Paschka, K. Dietz, C. Bokemeyer, 2003, Annals of the New York Academy of Sciences.

A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphobla

H. Gschaidmeier, B. Wassmann, D. Hoelzer, 2003, Annals of Hematology.

AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms.

H. Gschaidmeier, K. Bock, H. Heel, 1998, Advances in enzyme regulation.

Growth modulation of hepatocytes and rat liver epithelial cells (WB-F344) by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

H. Gschaidmeier, K. Bock, B. Bock-Hennig, 1996, Carcinogenesis.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-mediated membrane translocation of c-Src protein kinase in liver WB-F344 cells

H. Gschaidmeier, K. Bock, C. Koehle, 1999, Archives of Toxicology.

Mono- and Diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7.

F. Oesch, A. Seidel, H. Gschaidmeier, 1999, Biochemical pharmacology.

Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases.

H. Gschaidmeier, K. Bock, H. Heel, 1999, Drug metabolism reviews.

myeloid leukemia expression of myeloblastin and a specific T-cell response in chronic , but not the ABL-kinase inhibitor imatinib (STI571), induces α Interferon

H. Gschaidmeier, R. Hehlmann, A. Neubauer, 2013 .

Interferon- (cid:1) , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a speciﬁc T-cell response in chronic myeloid leukemia

S. Wölfl, H. Gschaidmeier, B. Wittig, 2002 .

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

E. Estey, Chunaram Choudhary, A. Gratwohl, 2005, Blood.

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

T. Lipp, C. Schoch, H. Gschaidmeier, 2004, Blood.

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2003, Leukemia.

Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

M. Lübbert, H. Gschaidmeier, O. Ottmann, 2003, Leukemia.

Neoimmun versus Neoral: a bioequivalence study in healthy volunteers and influence of a fat-rich meal on the bioavailability of Neoimmun

H. Gschaidmeier, L. Faerber, R. Seifert, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2013 .

ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2009 .

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2002, Leukemia.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Thomas Becker, Klemens Budde, Petra Reinke, 2011, The Lancet.

Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases.

B. Burchell, H. Gschaidmeier, K. Bock, 1993, Biochemical pharmacology.

Comparative Bioavailability of the Microemulsion Formulation of Cyclosporine (Neoral) With a Generic Dispersion Formulation (Cicloral) in Young Healthy Male Volunteers

H. Gschaidmeier, G. Mikus, L. Faerber, 2006, Therapeutic drug monitoring.

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

W. Hofmann, M. Lübbert, H. Gschaidmeier, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.

W. Hofmann, H. Koeffler, H. Gschaidmeier, 2003, Blood.

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

David Elashoff, H Phillip Koeffler, S. de Vos, 2002, The Lancet.

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

S. de Vos, W. Hofmann, H. Koeffler, 2002, Blood.

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.

P. Malfertheiner, Jie Chen, H. Gschaidmeier, 2006, Cancer letters.

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Armin Buschauer, Gert Fricker, A. Buschauer, 2002, The Journal of clinical investigation.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

G. Lenz, A. Ganser, L. Kanz, 2006 .

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission

P. Paschka, C. Schoch, H. Gschaidmeier, 2003, Leukemia.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

J. Oldenburg, H. Gschaidmeier, A. Pavlova, 2005 .

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

A. Marx, H. Gschaidmeier, F. Breitenbuecher, 2003, Blood.

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2003, Blood.

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

H. Gschaidmeier, A. Hochhaus, O. Ottmann, 2005 .

Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.

H. Gschaidmeier, O. Ottmann, M. Bornhäuser, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A prospective and randomised clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an initial therapy of advanced pancreatic cancer

P. Malfertheiner, H. Lippert, H. Gschaidmeier, 2004 .

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

M. Lübbert, H. Gschaidmeier, O. Ottmann, 2003, Leukemia.

Mono- and diglucuronide formation from chrysene and benzo(a)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1).

A. Seidel, B. Burchell, H. Gschaidmeier, 1992, Molecular pharmacology.

Formation of mono- and diglucuronides and other glycosides of benzo(a)pyrene-3,6-quinol by V79 cell-expressed human phenol UDP-glucuronosyltransferases of the UGT1 gene complex.

A. Seidel, B. Burchell, H. Gschaidmeier, 1995, Biochemical pharmacology.

Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy

Martin C. Müller, B. Druker, C. Schoch, 2001 .

Radiation inactivation analysis of microsomal UDP-glucuronosyltransferases catalysing mono- and diglucuronide formation of 3,6-dihydroxybenzo(a)pyrene and 3,6-dihydroxychrysene.

H. Gschaidmeier, K. Bock, 1994, Biochemical pharmacology.

Detection and separation of the S-adenosylmethionine-decarboxylase inhibitor SAM486A in human plasma and urine by reversed-phase ion-pairing high-performance liquid chromatography.

W. Hiddemann, W. Kern, H. Gschaidmeier, 2001, Journal of pharmacological and toxicological methods.

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

H. Gschaidmeier, O. Ottmann, B. Wassmann, 2004 .

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, O. Ottmann, M. Bornhäuser, 2006, Blood.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-mediated membrane translocation of c-Src protein kinase in liver WB-F344 cells

H. Gschaidmeier, K. Bock, C. Koehle, 1999, Archives of Toxicology.